Frequency Therapeutics' FX-322 Data Published In Peer-Reviewed Journal

By Vandana Singh5 days ago

  • Frequency Therapeutics Inc (NASDAQ: FREQ) has announced the publication of its lead candidate FX-322 Phase 1/2 study results in Otology & Neurotology. The data was initially announced in April 2019.
  • The data showed hearing improvements in adults with acquired sensorineural hearing loss (SNHL) ...

Full story available on Benzinga.com

Continue read on benzinga.com